Cargando…

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms

Ruxolitinib, a JAK1 and JAK2 inhibitor drug, has recently been approved for the treatment of patients with high- or intermediate-risk myelofibrosis with symptomatic splenomegaly. Ruxolitinib is the first clinically useful targeted therapy in Philadelphia chromosome-negative myeloproliferative neopla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eliaçık, Eylem, Işık, Ayşe, Aksu, Salih, Üner, Ayşegül, Büyükaşık, Yahya, Sayınalp, Nilgün, Göker, Hakan, Özcebe, Osman İ., Haznedaroğlu, İbrahim C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2015
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451485/ https://www.ncbi.nlm.nih.gov/pubmed/26316485 http://dx.doi.org/10.4274/tjh.2013.0265

Ejemplares similares

The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
por: Işık, Ayşe, et al.
Publicado: (2013)

Co-expression of t(15;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature
por: UZ, Burak, et al.
Publicado: (2013)

Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems
por: Bektaş, Özlen, et al.
Publicado: (2016)

Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency
por: ALADAĞ, Elifcan, et al.
Publicado: (2019)

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation
por: Çiftçiler, Rafiye, et al.
Publicado: (2021)

Identification of clinical and simple laboratory variables predicting responsible gastrointestinal lesions in patients with iron deficiency anemia
por: Serefhanoglu, Songul, et al.
Publicado: (2010)

The Prognosis of Adult Burkitt’s Cell Leukemia in Real-Life Clinical Practice
por: Malkan, Ümit Yavuz, et al.
Publicado: (2016)

The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia
por: Çiftçiler, Rafiye, et al.
Publicado: (2020)

CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation
por: ALADAĞ, Elifcan, et al.
Publicado: (2020)

Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at Diagnosis
por: Çiftçiler, Rafiye, et al.
Publicado: (2020)

Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study
por: Çiftçiler, Rafiye, et al.
Publicado: (2019)

The Factors Affecting Early Death in Newly Diagnosed APL Patients
por: Ciftciler, Rafiye, et al.
Publicado: (2019)

Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma
por: OKAY, Müfide, et al.
Publicado: (2019)

Indications and Outcomes of Splenectomy for Hematological Disorders
por: Ciftciler, Rafiye, et al.
Publicado: (2019)

Local Renin-Angiotensin System in Normal Hematopoietic and Multiple Myeloma-Related Progenitor Cells
por: Uz, Burak, et al.
Publicado: (2014)

Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem cell transplantation
por: KARATAŞ, Ayşe, et al.
Publicado: (2022)

Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in Remission
por: Aydın, Mürüvvet Seda, et al.
Publicado: (2017)

The effects of blood group types on the risk of COVID-19 infection and its clinical outcome
por: GÖKER, Hakan, et al.
Publicado: (2020)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients
por: KARATAŞ, Ayşe, et al.
Publicado: (2021)

A single-center experience of haploidentical stem cell transplantation in hematological malignancies
por: MALKAN, Ümit Yavuz, et al.
Publicado: (2022)

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019)

Prophylactic Central Nervous System Irradiation Is Not Indispensable in Adult Patients with Acute Lymphoblastic Leukemia: A Multicenter Retrospective Cohort Study
por: Çınar, Olgu Erkin, et al.
Publicado: (2022)

Nasal Natural Killer/T-cell Lymphoma with Skin, Eye, and Peroneal Nerve Involvement
por: Türker, Burcu, et al.
Publicado: (2012)

Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma
por: Ghasemi, Mehdi, et al.
Publicado: (2016)

Late Onset and Protracted Course of Steroid Refractory Chronic Graft-versus-Host Disease
por: Gunes, Gursel, et al.
Publicado: (2015)

Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis
por: Çınar, Olgu Erkin, et al.
Publicado: (2020)

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2015)

Potential pharmacobiological and hormonal effects on resuscitation
por: Wigginton, J, et al.
Publicado: (2006)

Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib
por: Tremblay, Douglas, et al.
Publicado: (2019)

Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma
por: Karataş, Ayşe, et al.
Publicado: (2020)

Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms
por: Yacoub, A., et al.
Publicado: (2014)

High Incidence of Herpes Zoster in Patients Using Ruxolitinib for Myeloproliferative Neoplasms: Need for Prophylaxis
por: te Linde, Elsemieke, et al.
Publicado: (2022)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group
por: Gupta, Vikas, et al.
Publicado: (2020)

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
por: Barbui, Tiziano, et al.
Publicado: (2021)

The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nrn70qaoqnkc3ggo9kn6taa4e8